Interview with Philippe Baudier, Managing Director, S.M.B. Laboratories
Mr Baudier, what inspired you when you joined the company back in 1978 and what are your main goals today? Prior to joining SMB Laboratories, I worked in a publishing…
Address: 26-28, rue de la Pastorale1080 – Brussels – Belgium
Tel: +32.2.411.48.28
S.M.B. is a Belgian based pharmaceutical company with global ambitions. Its objective is to become a leading European player in the field of oral and pulmonary drug delivery systems by being an innovative actor in the pharmaceutical industry.
Thanks to the success of its R&D Department, S.M.B. has become internationally recognized in the field of human health care in various high-tech areas such as Micropellets (microgranules for once daily administration), Lidose® (semi-solid lipidic matrix in hard capsule formulation), Divule® (high gloss gelatine coated tabs), DPI (Dry Powder Inhaler) and Effervescent Tablets design and large scale production.
Together with its exclusive partners, S.M.B. Technology S.A. (Contract Manufacturing) and GALEPHAR M/F (Contract R&D), Laboratoires SMB’s activity embraces a large spectrum of competences in initial R&D, continuous R&D, Clinical Trials, Analytics, production, Regulatory Affairs and Marketing, supporting a pipeline of in-house formulations.
S.M.B. proposes a balanced portfolio of products mainly in:
Respiratory tract
Cardiovascular system
Pain management
OTC
Mr Baudier, what inspired you when you joined the company back in 1978 and what are your main goals today? Prior to joining SMB Laboratories, I worked in a publishing…
Germany and Belgium have long held an important trading relationship, says Margit Kunz of AHK Debelux, the German chamber of commerce in Belgium and Luxembourg. She outlines some of the…
Perhaps to the surprise of many, Belgium is the world’s second-largest producer of vaccines, behind only the US, and – capitalising on its years of experience in the field –…
Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels is now looking to reshape the future of cancer care with the previously struggling biotech he…
Belgian healthcare performs strongly across most metrics and international comparisons, but – as elsewhere – there remains room for improvement in terms of integrating patient feedback and experience into the…
20-year Astellas veteran Mark Dekker – now back in his home country of the Netherlands and overseeing the Benelux cluster having primarily developed his career in emerging European markets –…
Marnix Denys of beMedTech – the Belgian association for the medical technology industry – outlines the agenda priorities for the organisation that he hopes will lead to a more value-driven…
RaDiOrg aims to support rare disease patients and patient organisations in Belgium, defend their interests, and raise awareness of what can be devastating and little-understood conditions. Director Eva Schoeters –…
The newly merged Port of Antwerp-Bruges is the world’s first GDP-compliant seaport. CCO Tom Hautekiet explains the significant role the Port is playing in global healthcare supply chains – leveraging…
Back home in Belgium after a stellar stint in Big Pharma, Dr Paul Stoffels* is now looking to reshape the future of cancer care with the biotech he helped co-found…
Univercells is a group of companies founded a decade ago based around the concept of revolutionizing the availability of biologics around the world through making essential medicines affordable to all,…
GSK has undergone a number of changes in recent years. After driving a major transformation that began in 2017 to strengthen its R&D performance, the British multinational suffered the impact…
The European Federation of Pharmaceutical Industries and Associations (EFPIA) has elected a new president and vice presidents who have set out a key priority for their term: a series of…
See our Cookie Privacy Policy Here
